v3.26.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Operating expenses:        
Research and development $ 34,365 $ 57,877 $ 83,644 $ 115,721
Selling, general and administrative 21,916 26,414 40,885 58,994
Total operating expenses 56,281 84,291 124,529 174,715
Loss from operations (56,281) (84,291) (124,529) (174,715)
Other income (expense):        
Research and development incentives 238 377 534 797
Investment income 1,880 3,696 3,840 8,411
Interest expense on finance lease liability (502) (518) (1,007) (1,039)
Interest expense on debt obligations (2,523) (1,488) (5,104) (2,963)
Other income (expense), net 67 (876) (621) (284)
Total other (expense) income, net (840) 1,191 (2,358) 4,922
Net loss $ (57,121) $ (83,100) $ (126,887) $ (169,793)
Net loss per common share, basic (in dollars per share) $ (0.54) $ (0.90) $ (1.26) $ (1.85)
Net loss per common share, diluted (in dollars per share) $ (0.54) $ (0.90) $ (1.26) $ (1.85)
Weighted average common shares outstanding, basic (in shares) 105,176,101 91,915,769 101,042,985 91,717,076
Weighted average common shares outstanding, diluted (in shares) 105,176,101 91,915,769 101,042,985 91,717,076